Search Results - "Lierman, E"

Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases by Lierman, E, Smits, S, Cools, J, Dewaele, B, Debiec-Rychter, M, Vandenberghe, P

Get full text

FIP1L1-PDGFRα D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRα T674I eosinophilic leukemia with single agent sorafenib by Lierman, E, Michaux, L, Beullens, E, Pierre, P, Marynen, P, Cools, J, Vandenberghe, P

“…Chronic eosinophilic leukemia (CEL) is a rare myeloproliferative neoplasm characterized by the FIP1L1-PDGFRA fusion gene, variant PDGFRA fusions or other…”
Get full text

The ability of sorafenib to inhibit oncogenic PDGFR{beta} and FLT3 mutants and overcome resistance to other small molecule inhibitors by Lierman, Els, Lahortiga, Idoya, Van Miegroet, Helen, Mentens, Nicole, Marynen, Peter, Cools, Jan

“…From the Department of Molecular and Developmental Genetics, Flanders Interuniversity Institute for Biotechnology (VIB), University of Leuven, Leuven, Belgium…”
Get full text

Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations by Al Assaf, Carla, Van Obbergh, Florence, Billiet, Johan, Lierman, Els, Devos, Timothy, Graux, Carlos, Hervent, Anne-Sophie, Emmerechts, Jan, Tousseyn, Thomas, De Paepe, Pascale, Papadopoulos, Petros, Michaux, Lucienne, Vandenberghe, Peter

“…The JAK2 V617F mutation, the thrombopoietin receptor MPL W515K/L mutation and calreticulin (CALR) mutations are mutually exclusive in essential thrombocythemia…”
Get full text

The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11) by WASAG, Bartosz, LIERMAN, Els, MEEUS, Peter, COOLS, Jan, VANDENBERGHE, Peter

“…We report a patient with T-lymphoblastic leukemia/lymphoma and a t(7;8)(q22;p11). CUX1 was identified as the fusion partner of FGFR1 by fluorescence in situ…”
Get full text

PF660 TRANSCRIPTIONAL PROFILES OF PRIMARY CULTURES OF ERYTHROID AND MEGAKARYOCYTIC CELLS IN ESSENTIAL THROMBOCYTHEMIA UNCOVER A HIGH DEGREE OF GENE DEREGULATION IN THE MEGAKARYOCYTIC LINEAGE by Papadopoulos, P., Smits, S., Gutiérrez, L., Werken, H., Lierman, E., Devos, T., Carreño, X. Guerrero, Van IJcken, W., Vandenberghe, P.

“…Background: Essential Thrombocythemia (ET) is a myeloproliferative neoplasm (MPN) characterized by megakaryocytic hyperplasia in the bone marrow and elevated…”
Get full text

Identification of protein tyrosine kinases with oncogenic potential using a retroviral insertion mutagenesis screen by Lierman, Els, Van Miegroet, Helen, Beullens, Els, Cools, Jan

“…1 Department of Molecular and Developmental Genetics, VIB, Leuven 2 Center for Human Genetics, KU Leuven, Leuven, Belgium Correspondence: Jan Cools, VIB11,…”
Get full text

ETV6 and PDGFRB: a license to fuse by Lierman, E., Cools, J.

Get full text

FIP1L1-PDGFR[alpha] D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFR[alpha] T674I eosinophilic leukemia with single agent sorafenib by Lierman, E, Michaux, L, Beullens, E, Pierre, P, Marynen, P, Cools, J, Vandenberghe, P

“…Chronic eosinophilic leukemia (CEL) is a rare myeloproliferative neoplasm characterized by the FIP1L1-PDGFRA fusion gene, variant PDGFRA fusions or other…”
Get full text

FIP1L1-PDGFRa D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRa T674I eosinophilic leukemia with single agent sorafenib by Lierman, E, Michaux, L, Beullens, E, Pierre, P, Marynen, P, Cools, J, Vandenberghe, P

“…Chronic eosinophilic leukemia (CEL) is a rare myeloproliferative neoplasm characterized by the FIP1L1-PDGFRA fusion gene, variant PDGFRA fusions or other…”
Get full text

FIP1L1-PDGFRα D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRα T6741 eosinophilic leukemia with single agent sorafenib by LIERMAN, E, MICHAUX, L, BEULLENS, E, PIERRE, P, MARYNEN, P, COOLS, J, VANDENBERGHE, P

“…Chronic eosinophilic leukemia (CEL) is a rare myeloproliferative neoplasm characterized by the FIP1L1-PDGFRA fusion gene, variant PDGFRA fusions or other…”
Get full text

FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib by Lierman, E, Michaux, L, Beullens, E, Pierre, P, Marynen, P, Cools, J, Vandenberghe, P

“…Chronic eosinophilic leukemia (CEL) is a rare myeloproliferative neoplasm characterized by the FIP1L1-PDGFRA fusion gene, variant PDGFRA fusions or other…”
Get full text

'To assure safe and healthful working conditions': taking lessons from labor unions to fulfill OSHA's promises by Lierman, Brooke E

Get full text